Saphnelo™ Approved as Self-Administered Autoinjector
The U.S. Food and Drug Administration just granted approval for a self-administered, once-weekly autoinjector of Saphenlo (anifrolumab), for the treatment of adult patients with systemic lupus erythematosus (SLE) on top of standard therapy. The decision was based on TULIP-SC Phase 3 trial results, which showed a statistically significant and clinically meaningful reduction in disease activity for participants with moderate to severe … Saphnelo™ Approved as Self-Administered Autoinjector